Welcome to our dedicated page for American Vanguard SEC filings (Ticker: AVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
American Vanguard Corporation's SEC filings document the formal disclosures of a NYSE-listed specialty agriculture products company and its AMVAC Chemical Corporation operating subsidiary. Recent Form 8-K reports cover operating results, earnings-call materials, Regulation FD disclosures and material credit arrangements, including term-loan and revolving-credit amendments tied to the company's capital structure and working-capital needs.
Proxy and annual-meeting filings address board elections, director composition, auditor ratification, executive compensation and shareholder voting matters. The filings also identify the company's common stock, par value, exchange listing and governance actions related to board size and committee-level oversight.
American Vanguard Corp (AVD) amended an insider Form 4 to correct previously reported holdings and explain changes in advisory authority. The filing discloses a disposition of 16,790 shares and states that a client of a separately managed account terminated its advisory agreement, removing Cruiser Capital's discretionary voting and dispositive authority over 411,398 shares; the termination involved no buy or sell transactions. The amendment corrects an earlier misstatement that reported 652,792 indirectly held shares; the filing clarifies the correct indirect holding is 789,284 shares.
Mark R. Bassett, a director of American Vanguard Corporation (AVD), reported the award of 17,621 deferred stock units (DSUs) on 08/07/2025 as part of the company’s non-management director compensation program. The DSUs are granted at $0, are nontransferable during the recipient’s service, and represent the right to receive one share of common stock upon settlement when the recipient’s service ends.
Following the award, the form shows 34,411 shares/units beneficially owned by the reporting person. No derivative securities were reported and the filing was submitted as an individual Form 4 by the director.
Carmen Tiu de Mino, a director of American Vanguard Corporation (AVD), was awarded 17,621 deferred stock units on 08/07/2025 as part of the company's non-management director compensation program. Each deferred stock unit (DSU) entitles the holder to one share upon settlement when the recipient's service with the company ends; DSUs are nontransferable and carry neither voting nor dividend rights during the remaining term of service.
Following the award, the reporting person beneficially owned 24,407 shares on a direct basis. The DSUs were issued at a recorded price of $0 and are subject to the company's standard DSU agreement.
Marisol Angelini, a director of American Vanguard Corp (AVD), reported on Form 4 that she was awarded 17,621 shares of common stock on 08/07/2025 as part of the companys compensation program for non-management directors related to the 2025 annual stockholders meeting. The award is reported at a price of $0 in the filing and is explained in an accompanying footnote.
Following the award, Angelini beneficially owns 36,890 shares. The Form 4 was signed on 08/08/2025 and filed by one reporting person. No derivative transactions are listed in Table II.
Gunter Emer, a director of American Vanguard Corporation (AVD), reported receiving 8,810 shares of common stock on 08/07/2025 as part of the company’s non-management director compensation program. The award was issued at $0 and increased his direct beneficial ownership to 33,723 shares.
The Form 4 shows no derivative securities and records the filing signature on 08/08/2025. The disclosure reflects a routine director equity award tied to the 2025 annual stockholders’ meeting rather than a market purchase or sale.
American Vanguard Corporation director Steven D. Macicek was awarded 17,621 deferred stock units (DSUs) on 08/07/2025 as part of the companys non-management director compensation program tied to the 2025 annual stockholders meeting. Each DSU represents the right to receive one share of common stock upon settlement.
The DSUs were granted at $0, are nontransferable during the recipients service, and carry no voting or dividend rights until settlement. Following the award the reporting persons beneficial ownership is reported as 48,839 shares.
American Vanguard Corporation (AVD) reported that director Scott Baskin was awarded 8,810 shares of common stock on 08/07/2025 as part of the company’s non-management director compensation program. The shares were granted at a price of $0, reflecting an award rather than an open-market purchase.
Following the grant, Mr. Baskin’s reported beneficial ownership increased to 41,997 shares. The filing identifies Mr. Baskin as a director and notes the award was connected to the 2025 annual stockholders' meeting. This is a routine equity award disclosed on Form 4 and does not include additional transactions or derivative positions.
Patrick E. Gottschalk, a director of American Vanguard Corporation (AVD), was awarded 17,621 deferred stock units (DSUs) on 08/07/2025 as part of the companys non-management director compensation program. Each DSU represents the right to receive one share of common stock upon settlement when the recipients service with the company ends; while outstanding the DSUs are nontransferable and carry neither voting nor dividend rights.
Following the award, Gottschalks reported beneficial ownership of AVD common stock is 79,424 shares (direct). The DSUs were granted at a reported price of $0 and are subject to the companys standard DSU agreement.
American Vanguard (AVD) Q2-25 10-Q highlights:
- Net sales grew 1% YoY to $129.3 m; U.S. crop +1%, U.S. non-crop +3%, International flat.
- Cost-of-sales fell 2%, lifting gross margin to 31% (29% LY). Gross profit +7% to $40.5 m.
- Operating expenses -23% to $36.2 m as transformation spending fell to $1.6 m (vs $7.3 m). Operating income swung to $4.4 m (-$9.2 m).
- After $4.5 m net interest and $0.8 m tax expense, quarterly net loss narrowed sharply to $0.8 m (-$11.7 m); EPS -$0.03.
- 1H-25: revenue -7% to $245.1 m; gross margin 29% (30% LY); operating break-even ($0.1 m); net loss $9.3 m vs -$10.2 m.
- Cash used in operations -$39.8 m (vs -$49.4 m LY) driven by $46.2 m drawdown of customer prepayments and $9.8 m inventory build.
- Debt climbed to $189.5 m (12/24: $147.3 m); average borrowing rate 8.4% Q2.
- May-25 Eleventh Amendment cut revolver to $245 m and suspended leverage & FCCR covenants through 2025, adding minimum liquidity & EBITDA tests. Company had $31.8 m available capacity at 6-30-25.
- No dividends permitted under amended facility.
- Material weaknesses in ICFR (Australia, close process, risk assessment) persist.
- Legal exposure: out-of-spec insecticide lots may create material claims; loss not yet estimable.
Management sees early ag-market recovery, expects lower transformation spend and continues talks to extend credit facility (matures Aug-26).